Developer docs
API playgroundTry for free, no card

Search company profiles

MALCOVA

Full company profile

uuid0000vqo

Namestring
MALCOVA
Legal namestring
Malcova, Inc.
Websiteurl
malcova.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

MALCOVA (Malcova, Inc.) is a Newark, California-based medical device startup developing a proprietary hardware-and-software imaging platform for early disease detection, with an initial clinical focus on breast cancer in women with dense breast tissue and acute stroke. The platform is built around four integrated innovations: a patented Narrow-Beam CT scanner that delivers scatter-free, gantry-free 3D imaging at substantially lower radiation doses than conventional CT; high-fidelity Digital Twins that simulate breast tissue morphology to produce bias-controllable AI training data; patient-derived Physical Twins (scan-ready phantoms) that enable repeatable imaging without radiation exposure; and an AI-based Diagnostic Agent intended to assist radiologists. Technical credibility is anchored in peer-reviewed publications in Medical Physics and Physics in Medicine & Biology, including work characterizing scatter contamination in breast CT. The company applies a vertical segmentation approach targeting two primary segments, women with dense breast tissue and the radiologists/healthcare providers serving them, with stroke detection referenced as an adjacent use case.

MALCOVA is pre-revenue and does not publicly disclose pricing. Its go-to-market is enterprise field-sales oriented, relying on direct outreach to hospitals, imaging centers, and healthcare systems through a contact-page and email (contact@malcova.com) motion, supplemented by LinkedIn presence and earned media (Forbes, PR Newswire). The company's capital history runs from non-dilutive SBIR grants from the National Science Foundation (2020, 2023) and the National Cancer Institute (2021), totaling approximately $1.645 million, to its first equity investment from RPV Fund in 2024. In October 2025, MALCOVA entered a three-way co-development partnership with Triple Ring and Leo Cancer Care to extend its imaging platform into upright radiation therapy for breast cancer. The company is founder-led by co-founders Dr. Peymon Ghazi (CEO, imaging physicist) and Dr. Tara Ghazi (CBO, cognitive neuroscientist), supported by a Head of Hardware and Head of Software, with total headcount of 1-10 employees.

Short descriptiontext

MALCOVA is a pre-revenue medical device startup developing a patented Narrow-Beam CT scanner, proprietary Digital and Physical Twin models, and an AI-based Diagnostic Agent for early breast cancer detection in dense breast tissue and stroke imaging. It is Newark, California-based and founder-led as of 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNewark, United States
HQ citystring
Newark
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breast cancer imaging, CT imaging devices, medical imaging hardware, AI diagnostic software, digital twin simulation
Industry4 codes
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAB
Computed Tomography (CT) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAFAKAD
Breast Imaging Centers (Mammography/Tomosynthesis)
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Imaging Technology Licensing/Sale
TypeHardware Sales
Description

Malcova generates revenue through the development and eventual commercialization of its proprietary medical imaging technology, including Narrow-Beam CT systems, digital and physical twins, and AI diagnostic software. As a pre-commercial or early-stage company, it has historically relied on non-dilutive SBIR funding and equity investment. Revenue streams are not yet publicly disclosed.

forbes.com
2SBIR Non-Dilutive Funding
TypeSubscription Recurring
Description

The company previously relied on Small Business Innovation Research (SBIR) non-dilutive funding from NIH and NSF between 2021 and 2024 to advance its technology development. SBIR authorization lapsed on September 30, 2025.

forbes.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MALCOVA develops and sells a proprietary medical imaging platform built around its patented Narrow-Beam CT hardware, which delivers scatter-free, gantry-free 3D breast imaging at significantly lower radiation doses than traditional CT. The platform is complemented by Digital Twins and Physical Twins for AI model training, and an AI-based Diagnostic Agent that assists radiologists with early disease detection. The company targets hospitals, imaging centers, and healthcare systems for breast cancer and stroke detection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Significantly lower radiation dose compared to traditional CT imaging
+2 more records
Product overview1 text field

MALCOVA offers a unified medical imaging platform centered on three core innovations: patented Narrow-Beam CT technology for scatter-free 3D breast imaging, Digital Twins for virtual anatomical simulation, and Physical Twins for realistic phantom models. An AI-based Diagnostic Agent integrates with these imaging systems to assist radiologists. The platform is designed for early breast cancer and stroke detection, particularly for women with dense breast tissue, emphasizing patient comfort, reduced radiation exposure, and superior diagnostic accuracy.

Product and service4 records
1Narrow-Beam CT
CategoryMedical Imaging Hardware
Description

A patented scatter-free cone-beam CT imaging system for breast and radiology applications, providing contamination-free, detailed 3D imaging at significantly lower radiation doses than traditional CT. It is gantry-free, mobile, and adaptive to variations in tissue type and breast diameter. Designed for radiologists, hospitals, and imaging centers performing early breast cancer and stroke detection.

2Digital Twins
CategoryAI Training Data / Simulation Software
Description

High-fidelity, computer-based models that simulate real breast tissue morphology and behavior, offering limitless, bias-controllable training data for AI development without patient risk. Aimed at AI developers, researchers, and healthcare providers building diagnostic algorithms.

3Physical Twins
CategoryMedical Imaging Phantoms / Hardware
Description

Realistic, scan-ready phantoms derived from actual patient images, enabling repeatable imaging and AI training without radiation risk to patients. Designed for research institutions, AI developers, and clinical teams needing consistent, patient-derived test subjects.

4AI-based Diagnostic Agent
CategoryAI Diagnostic Software
Description

An intelligent software assistant that relieves radiologist burden and reveals novel diagnostic insights to support early disease detection. Processes breast and radiology imaging to detect diseases at earliest stages with superior accuracy. Designed for radiologists, oncologists, and imaging centers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

Triple Ring partnered with Malcova and Leo Cancer Care during Breast Cancer Awareness Month 2025 to develop patient-focused breast imaging and upright radiation therapy systems. The collaboration aims to improve early detection accuracy and treatment precision while reducing patient discomfort and anxiety.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

Leo Cancer Care joined Malcova and Triple Ring in a三方 partnership to develop patient-focused breast imaging and upright radiation therapy systems. The collaboration focuses on improving early detection accuracy and treatment precision.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hologic is the dominant player in breast imaging hardware (Selenia Dimensions mammography, 3D tomosynthesis, I-View software), directly competing with Malcova's intended breast cancer detection use case for the same healthcare providers and radiologists.

TypeDirect peer
Description

Koning Health produces a competing cone-beam breast CT (KBCT) system and is the closest direct competitor to Malcova's Narrow-Beam CT, targeting the same dense-breast imaging market with a similar non-compression, 3D imaging approach.

TypeBroad incumbent
Description

GE HealthCare is a broad incumbent across CT, mammography, and AI imaging analytics (e.g., Senographe Pristina, Edison platform). It overlaps with Malcova in CT and breast imaging as part of a much larger portfolio of medical imaging systems.

TypeBroad incumbent
Description

Siemens Healthineers manufactures CT systems (SOMATOM family) and women's health imaging, representing a broad incumbent competitor with deep R&D resources, established hospital relationships, and regulatory infrastructure Malcova must compete against.

TypeBroad incumbent
Description

Philips offers broad medical imaging portfolios including CT, mammography, and AI-enabled diagnostic tools. It is a broad incumbent competitor across the radiology market where Malcova intends to commercialize.

TypeEmerging player
Description

iCAD provides AI-powered breast cancer detection and breast density assessment software (ProFound AI), directly comparable to Malcova's AI-based Diagnostic Agent and Digital Twins capabilities in serving radiologists' workflow needs.

TypeEmerging player
Description

Volpara Health offers breast imaging analytics software focused on density assessment, risk evaluation, and mammography reporting—targeting the same dense-breast patient population and radiologist workflow as Malcova's software offerings.

TypeEmerging player
Description

ScreenPoint Medical develops AI software (Transpara) for breast imaging analysis and decision support, competing with Malcova's AI Diagnostic Agent in delivering radiologist-assistive AI capabilities for earlier cancer detection.

TypeBroad incumbent
Description

Fujifilm Healthcare manufactures mammography systems, CT scanners, and women's imaging solutions, making it a broad incumbent competitor across the medical imaging categories where Malcova intends to compete.

10Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec provides optical and digital imaging systems for ophthalmology, surgery, and diagnostics. It represents an adjacent incumbent with deep optical engineering expertise comparable to Malcova's patented imaging approach, though in different clinical verticals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MALCOVA

Medical Imaging Devicesmalcova.com

MALCOVA is a pre-revenue medical device startup developing a patented Narrow-Beam CT scanner, proprietary Digital and Physical Twin models, and an AI-based Diagnostic Agent for early breast cancer detection in dense breast tissue and stroke imaging. It is Newark, California-based and founder-led as of 2025.

What MALCOVA does

MALCOVA (Malcova, Inc.) is a Newark, California-based medical device startup developing a proprietary hardware-and-software imaging platform for early disease detection, with an initial clinical focus on breast cancer in women with dense breast tissue and acute stroke. The platform is built around four integrated innovations: a patented Narrow-Beam CT scanner that delivers scatter-free, gantry-free 3D imaging at substantially lower radiation doses than conventional CT; high-fidelity Digital Twins that simulate breast tissue morphology to produce bias-controllable AI training data; patient-derived Physical Twins (scan-ready phantoms) that enable repeatable imaging without radiation exposure; and an AI-based Diagnostic Agent intended to assist radiologists. Technical credibility is anchored in peer-reviewed publications in Medical Physics and Physics in Medicine & Biology, including work characterizing scatter contamination in breast CT. The company applies a vertical segmentation approach targeting two primary segments, women with dense breast tissue and the radiologists/healthcare providers serving them, with stroke detection referenced as an adjacent use case.

MALCOVA is pre-revenue and does not publicly disclose pricing. Its go-to-market is enterprise field-sales oriented, relying on direct outreach to hospitals, imaging centers, and healthcare systems through a contact-page and email (contact@malcova.com) motion, supplemented by LinkedIn presence and earned media (Forbes, PR Newswire). The company's capital history runs from non-dilutive SBIR grants from the National Science Foundation (2020, 2023) and the National Cancer Institute (2021), totaling approximately $1.645 million, to its first equity investment from RPV Fund in 2024. In October 2025, MALCOVA entered a three-way co-development partnership with Triple Ring and Leo Cancer Care to extend its imaging platform into upright radiation therapy for breast cancer. The company is founder-led by co-founders Dr. Peymon Ghazi (CEO, imaging physicist) and Dr. Tara Ghazi (CBO, cognitive neuroscientist), supported by a Head of Hardware and Head of Software, with total headcount of 1-10 employees.

MALCOVA firmographics

Firmographics
Name
MALCOVA
Legal name
Malcova, Inc.
Website
https://malcova.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
MALCOVA is a pre-revenue medical device startup developing a patented Narrow-Beam CT scanner, proprietary Digital and Physical Twin models, and an AI-based Diagnostic Agent for early breast cancer detection in dense breast tissue and stroke imaging. It is Newark, California-based and founder-led as of 2025.
Ownership category
akta.pro rank

MALCOVA industry classification

Industry
Product category
Medical Imaging Devices
NAICS
Irradiation Apparatus Manufacturing (334517), Surgical and Medical Instrument Manufacturing (339112)
SIC
X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAB
Computed Tomography (CT) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAFAKAD
Breast Imaging Centers (Mammography/Tomosynthesis)

Keywords

  • Breast cancer imaging
  • CT imaging devices
  • Medical imaging hardware
  • AI diagnostic software
  • Digital twin simulation

Where MALCOVA is headquartered

Location

Headquarters

HQ city
Newark
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MALCOVA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Imaging Technology Licensing/Sale: Malcova generates revenue through the development and eventual commercialization of its proprietary medical imaging technology, including Narrow-Beam CT systems, digital and physical twins, and AI diagnostic software. As a pre-commercial or early-stage company, it has historically relied on non-dilutive SBIR funding and equity investment. Revenue streams are not yet publicly disclosed.
  2. SBIR Non-Dilutive Funding: The company previously relied on Small Business Innovation Research (SBIR) non-dilutive funding from NIH and NSF between 2021 and 2024 to advance its technology development. SBIR authorization lapsed on September 30, 2025.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

MALCOVA product offering

Product offering

Core offering

MALCOVA develops and sells a proprietary medical imaging platform built around its patented Narrow-Beam CT hardware, which delivers scatter-free, gantry-free 3D breast imaging at significantly lower radiation doses than traditional CT. The platform is complemented by Digital Twins and Physical Twins for AI model training, and an AI-based Diagnostic Agent that assists radiologists with early disease detection. The company targets hospitals, imaging centers, and healthcare systems for breast cancer and stroke detection.

Product overview

MALCOVA offers a unified medical imaging platform centered on three core innovations: patented Narrow-Beam CT technology for scatter-free 3D breast imaging, Digital Twins for virtual anatomical simulation, and Physical Twins for realistic phantom models. An AI-based Diagnostic Agent integrates with these imaging systems to assist radiologists. The platform is designed for early breast cancer and stroke detection, particularly for women with dense breast tissue, emphasizing patient comfort, reduced radiation exposure, and superior diagnostic accuracy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Narrow-Beam CT A patented scatter-free cone-beam CT imaging system for breast and radiology applications, providing contamination-free, detailed 3D imaging at significantly lower radiation doses than traditional CT. It is gantry-free, mobile, and adaptive to variations in tissue type and breast diameter. Designed for radiologists, hospitals, and imaging centers performing early breast cancer and stroke detection.
  • Digital Twins High-fidelity, computer-based models that simulate real breast tissue morphology and behavior, offering limitless, bias-controllable training data for AI development without patient risk. Aimed at AI developers, researchers, and healthcare providers building diagnostic algorithms.
  • Physical Twins Realistic, scan-ready phantoms derived from actual patient images, enabling repeatable imaging and AI training without radiation risk to patients. Designed for research institutions, AI developers, and clinical teams needing consistent, patient-derived test subjects.
  • AI-based Diagnostic Agent An intelligent software assistant that relieves radiologist burden and reveals novel diagnostic insights to support early disease detection. Processes breast and radiology imaging to detect diseases at earliest stages with superior accuracy. Designed for radiologists, oncologists, and imaging centers.

Quantifiable outcome

  • Significantly lower radiation dose compared to traditional CT imaging
  • +2 more outcomes

Companies that use MALCOVA

Customer profile

Segments2 records

Ideal customer profiles1 record

MALCOVA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

MALCOVA partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Triple RingcoreStrategic or Co-development Partner · 14 October 2025Triple Ring partnered with Malcova and Leo Cancer Care during Breast Cancer Awareness Month 2025 to develop patient-focused breast imaging and upright radiation therapy systems. The collaboration aims to improve early detection accuracy and treatment precision while reducing patient discomfort and anxiety.
  • Leo Cancer CareminorStrategic or Co-development Partner · 14 October 2025Leo Cancer Care joined Malcova and Triple Ring in a三方 partnership to develop patient-focused breast imaging and upright radiation therapy systems. The collaboration focuses on improving early detection accuracy and treatment precision.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

MALCOVA competitors and assessment

Company assessment

Direct peers

  • Hologic: Hologic is the dominant player in breast imaging hardware (Selenia Dimensions mammography, 3D tomosynthesis, I-View software), directly competing with Malcova's intended breast cancer detection use case for the same healthcare providers and radiologists.
  • Koning Health: Koning Health produces a competing cone-beam breast CT (KBCT) system and is the closest direct competitor to Malcova's Narrow-Beam CT, targeting the same dense-breast imaging market with a similar non-compression, 3D imaging approach.

Broad incumbents

  • GE HealthCare: GE HealthCare is a broad incumbent across CT, mammography, and AI imaging analytics (e.g., Senographe Pristina, Edison platform). It overlaps with Malcova in CT and breast imaging as part of a much larger portfolio of medical imaging systems.
  • Siemens Healthineers: Siemens Healthineers manufactures CT systems (SOMATOM family) and women's health imaging, representing a broad incumbent competitor with deep R&D resources, established hospital relationships, and regulatory infrastructure Malcova must compete against.
  • Philips Healthcare: Philips offers broad medical imaging portfolios including CT, mammography, and AI-enabled diagnostic tools. It is a broad incumbent competitor across the radiology market where Malcova intends to commercialize.
  • Fujifilm Healthcare: Fujifilm Healthcare manufactures mammography systems, CT scanners, and women's imaging solutions, making it a broad incumbent competitor across the medical imaging categories where Malcova intends to compete.
  • Carl Zeiss Meditec: Carl Zeiss Meditec provides optical and digital imaging systems for ophthalmology, surgery, and diagnostics. It represents an adjacent incumbent with deep optical engineering expertise comparable to Malcova's patented imaging approach, though in different clinical verticals.

Emerging players

  • iCAD: iCAD provides AI-powered breast cancer detection and breast density assessment software (ProFound AI), directly comparable to Malcova's AI-based Diagnostic Agent and Digital Twins capabilities in serving radiologists' workflow needs.
  • Volpara Health: Volpara Health offers breast imaging analytics software focused on density assessment, risk evaluation, and mammography reporting—targeting the same dense-breast patient population and radiologist workflow as Malcova's software offerings.
  • ScreenPoint Medical: ScreenPoint Medical develops AI software (Transpara) for breast imaging analysis and decision support, competing with Malcova's AI Diagnostic Agent in delivering radiologist-assistive AI capabilities for earlier cancer detection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

MALCOVA social profiles

Digital presence

MALCOVA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MALCOVA leadership team

Management profile

Number of profiles

Profiles4 records

MALCOVA funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MALCOVA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MALCOVA

What does MALCOVA do?

MALCOVA develops and sells a proprietary medical imaging platform built around its patented Narrow-Beam CT hardware, which delivers scatter-free, gantry-free 3D breast imaging at significantly lower radiation doses than traditional CT. The platform is complemented by Digital Twins and Physical Twins for AI model training, and an AI-based Diagnostic Agent that assists radiologists with early disease detection. The company targets hospitals, imaging centers, and healthcare systems for breast cancer and stroke detection.

Is MALCOVA a public or private company?

MALCOVA is a private company. It is classified as venture growth investor backed and is currently operating.

When was MALCOVA founded?

MALCOVA was founded in 2021. It employs 1 to 10 people.

Where is MALCOVA based?

MALCOVA is headquartered in Newark, United States, in the North America region.

How does MALCOVA make money?

Two revenue lines are on record. Medical Imaging Technology Licensing/Sale is the primary driver. The others are SBIR Non-Dilutive Funding.

Who are MALCOVA's main competitors?

Direct peers on record are Hologic and Koning Health. Broad incumbents are GE HealthCare, Siemens Healthineers, Philips Healthcare, Fujifilm Healthcare and Carl Zeiss Meditec. Emerging players are iCAD, Volpara Health and ScreenPoint Medical.

Does MALCOVA have an API?

No public API is recorded for MALCOVA.

What industry is MALCOVA in?

MALCOVA's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHABAF, Mammography & Breast Imaging Systems, with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 334517 and its SIC code is 3844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesSBIR Funding For Medical Innovation Has StalledMALCOVA, a medical imaging startup developing breast cancer detection technology for women with dense breast tissue, relied on SBIR non-dilutive funding from 2021 to 2024 to advance its technology before securing its first equity investment from rpv fund in 2024. SBIR authorization lapsed on September 30, 2025, and remains stalled in Congress, pausing new awards from agencies like the NIH and NSF and creating uncertainty around matched funding mechanisms that reduce investor risk. The broader concern is that disruption to SBIR threatens the innovation infrastructure that helps early-stage medical companies progress from technical feasibility to market readiness.VenturewellPowering Women’s Health Innovators and StartupsVenture capital investment in women's health more than tripled between 2019 and 2024, outpacing overall healthcare investment growth, driven by recognition that health conditions affect women differently and disproportionately. The $113 million commitment from the White House Initiative on Women's Health Research and ARPA-H, administered through VentureWell's Investor Catalyst Hub, has supported innovators including CONNEQT Health, Daré Bioscience, and Malcova to advance solutions from endometriosis diagnostics to maternal health devices. Organizations like VentureWell continue to bridge the 'valley of death' funding gap for women's health startups, though women-focused companies still receive only 4% of total healthcare VC investment despite women making over 80% of healthcare decisions.PR NewswireThis Breast Cancer Awareness Month, Patient-First Innovation -- In Collaboration with Triple RingTriple Ring Technologies announced collaborations with Malcova and Leo Cancer Care to develop patient-focused breast cancer care technologies. Malcova has created a next-generation breast imaging platform using narrow-beam 3D imaging and digital twin technologies designed to improve accuracy for women with dense breast tissue, while Leo Cancer Care developed the Marie system, an upright radiation therapy platform that treats patients in a seated position for greater comfort and precision. These partnerships aim to reduce barriers to early detection and treatment completion by addressing patient fear, discomfort, and disruption in breast cancer care.